Modern Glioma Management

Name: Modern Glioma Management: Integrating Molecular Markers and New Targeted Therapies
Uploaded: 2025-12-02T15:24:00+00:00
Duration: 13 min 47 s
Description: Patrick Y. Wen, MD, Dana-Farber Cancer Institute, Boston, MA, discusses current standards of care for low- and high-grade gliomas, including the importance

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Neuro-Oncology Outlook: IDH-Mutant Glioma—Clinical Insights and Emerging Directions
Neuro-Oncology Outlook: IDH-Mutant Glioma—Clinical Insights and Emerging Directions
Neuro-oncology
Neuro-Oncology Outlook: IDH-Mutant Glioma—Clinical Insights and Emerging Directions
Tyler A. Lanman, MD
Tyler A. Lanman, MD
Artificial Intelligence in Clinical Neurology: Opportunities, Limitations, and the Path Forward
Artificial Intelligence in Clinical Neurology: Opportunities, Limitations, and the Path Forward
Imaging & Testing
Artificial Intelligence in Clinical Neurology: Opportunities, Limitations, and the Path Forward
Aysha Jadran, MD; Saqib A. Chaudhry, MD
Aysha Jadran, MD; Saqib A. Chaudhry, MD
Care of Individuals with Neurofibromatosis Type 1 Amid an Evolving Paradigm of Therapeutic Development
Care of Individuals with Neurofibromatosis Type 1 Amid an Evolving Paradigm of Therapeutic Development
Neuro-oncology
Care of Individuals with Neurofibromatosis Type 1 Amid an Evolving Paradigm of Therapeutic Development
Alyssa Lucas, MD; Mina Lobbous, MD
Alyssa Lucas, MD; Mina Lobbous, MD
RENEU (A Study to Evaluate the Safety, Effectiveness, and Tolerability of Gomekli in Children Aged ≥2 Years and Adults with an Inoperable NF1-PN; NCT03962543)
RENEU (A Study to Evaluate the Safety, Effectiveness, and Tolerability of Gomekli in Children Aged ≥2 Years and Adults with an Inoperable NF1-PN; NCT03962543)
Neuro-oncology
RENEU (A Study to Evaluate the Safety, Effectiveness, and Tolerability of Gomekli in Children Aged ≥2 Years and Adults with an Inoperable NF1-PN; NCT03962543)
Christopher Moertel, MD
Christopher Moertel, MD